GlassScriptPhysician profile
Michael C Nelms
NPI 1639255458
$563.27
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $191 · 2022: $259 · 2023: $73.93 · 2024: $39.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $113.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $124.22 | 2022-2023 | Seglentis |
| Abbott Laboratories | $115.04 | 2022 | |
| Endo Pharmaceuticals INC. | $109.05 | 2021-2023 | Xiaflex |
| Pacira Pharmaceuticals Incorporated | $47.87 | 2022-2023 | Zilretta, Iovera, Exparel |
| Kerecis Limited | $39.59 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
| Trevena, INC. | $18.77 | 2021 | |
| Horizon Therapeutics Plc | $14.61 | 2022 | |
| Stryker Corporation | $14.59 | 2021 | |
| Radius Health, INC. | $14.07 | 2021 | |
| Pfizer INC. | $13.78 | 2021 | |
| Pacira Therapeutics, INC. | $13.63 | 2021 | |
| Ferring Pharmaceuticals INC. | $13.58 | 2021 | |
| Heron Therapeutics, INC. | $12.57 | 2021 | |
| Alon Medical Technology | $11.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Nelms listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.